Prediction of adverse clinical outcomes in patients with cardiogenic shock after open heart surgery with intra-aortic ballon contrapulsation

Aim. To determine preimplantation risk factors and predictors of unfavorable outcome in patients with cardiogenic shock after open-heart surgery, who had an intraoperative system of mechanical circulatory support – intra-aortic balloon contrapulsation.
Methods. A retrospective study was conducted at the Republican Scientific and Practical Center “Cardiology” for 2015–2020. It included 66 patients who underwent heart surgery on bypass and who intraoperatively developed cardiogenic shock, refractory to drug therapy, which resulted in the use of intra-aortic balloon counterpulsation. The diagnosis of cardiogenic shock was determined based on the generally accepted criteria, as well as based on the SCAI (Society for Cardiovascular Angiography and Interventions) classification of shock: systolic blood pressure < 90 mmHg for > 30 minutes or the need for infusion of vasopressors or inotropes to achieve the blood pressure of ≥ 90 mm Hg. The Pearson Chi-square test used for nonparametric analysis of qualitative characteristics. The predictors were identified based on logistic regression. Differences were considered significant at p < 0.05 (5%). Results. Risk factors for adverse outcome in case of CS before the use of IABP were: age over 65 years OR = 6.04 [95% CI 1.73 – 21.06], p = 0.003; female gender OR = 3.24 [95% CI 1.064 – 9.873], p = 0.048; vasoactive and inotropic support of more than 42 points OR = 7.85 [95% CI 2.33 – 26.45], p = 0.001; blood lactate of more than 4.7 mmol/l OR = 4.12 [95% CI 1.27 – 13.37], p = 0.014; blood acidity pH < 7.33 OR = 6.34 [95% CI 1.97 – 20.37], p = 0.003; base deficit BE > –5.6 OR = 7.32 [95% CI 2.19 – 24.42], p = 0.001. According to the β-coefficients of the logistic regression equation, predictors were scored as follows: age > 65 years = 2 points, VIP > 42 = 2 points, lactate > 4.7 mmol/L = 1 point. The cumulative probability of 30-day mortality was as follows: 9% when defined as 1 point, 20% – 2 points, 55% – 3 points, 60% – 4 points, 75% – 5 points (Chi-square 24.1; df = 5; p = 0.001).
Conclusions. Cardiogenic shock is a fatal complication in cardiac surgery. The use of vasopressor and inotropic drugs has an important role in the treatment of CS; however, escalation of catecholamine doses leads to the progression of multiple organ failure due to hypoperfusion and hypoxia of target organs. Therefore, the use of intra-aortic balloon counterpulsation can improve the results of CS treatment. However, the effect of IABP is limited to increasing cardiac output by no more than 1 l/minute. Based on the calculator we developed, when determining a high risk of an unfavorable outcome of the IABP use, options for circulatory support should be considered including extracorporeal membrane oxygenation, ventricular assist device.

1. Van Diepen S., Katz J.N., Albert N.M., Henry T.D., Jacobs A.K., Kapur N.K., Kilic A., Menon V., Ohman E.M., Sweitzer N.K., Thiele H., Washam J.B., Cohen M.G. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation, 2017, vol. 136, issue 16, pp. 232–268. doi: 10.1161/CIR.0000000000000525.

2. Maganti M., Rao V., Borger M.A., Ivanov J., David T.E. Predictors of low cardiac output syndrome after isolated aortic valve surgery. Circulation, 2005, vol. 112(9 Suppl), pp. 488–452. doi: 10.1161/CIRCULATIONAHA.104.526087.

3. Rajendra H.M., Grab J.D., O’Brien S.M., Glower D.D., Haan C.K., Gammie J.S., Peterson E.D. ; Society of Thoracic Surgeons National Cardiac Database Investigators. Clinical characteristics and in-hospital outcomes of patients with cardiogenic shock undergoing coronary artery bypass surgery. Circulation, 2008, vol. 117, issue 7, pp. 876–885. doi: 10.1161/CIRCULATIONAHA.107.728147.

4. Favia I., Vitale V., Ricci Z. The vasoactive-inotropic score and levosimendan: Time for LVIS? J Cardiothorac Vasc Anesth, 2013, vol. 27, pp. 15–16. doi:10.1053/j.jvca.2012.11.009.

5. White J.M., Ruygrok P.N. Intra-aortic balloon counterpulsation in contemporary practice – where are we? Heart Lung Circ, 2015, vol. 24(4), pp. 335–341. doi: 10.1016/j.hlc.2014.12.003.

6. Van de Werf F., Bax J., Betriu A., Blomstrom-Lundqvist C., Crea F., Falk V., Filippatos G., Fox K., Huber K., Kastrati A., Rosengren A., Steg P.G., Tubaro M., Verheugt F., Weidinger F., Weis M. ; ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J, 2008, vol. 29(23), pp. 2909–2945. doi: 10.1093/eurheartj/ehn416.

7. O’Gara P., Kushner F.G., Ascheim D.D., Casey Jr D.E., Chung M.K., et. al. 2013ACCF/AHA guideline for management of ST-elevation myorcadial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2013, vol. 127(4), pp. e362-425. doi: 10.1161/CIR.0b013e3182742cf6.

8. Ibanez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci C., Bueno H Caforio., A.L.P., Crea F., Goudevenos J.A., Halvorsen S., Hindricks G., Kastrati A., Lenzen M.J., Prescott E., Roffi M., Valgimigli M., Varenhorst C., Vranckx P., Widimský P.; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 2018, vol. 39, issue 2, pp. 119–177. doi: 10.1093/eurheartj/ehx393.

9. Maxwell B.G., Powers A.J., Sheikh A.Y., Lee P.H., Lobato R.L., Wong J.K. Resource use trends in extracorporeal membrane oxygenation in adults: an analysis of the Nationwide Inpatient Sample 1998-2009. Thorac Cardiovasc Surg, 2014, vol. 148(2), pp. 416–421. doi: 10.1016/j.jtcvs.2013.09.033.

10. Lomivorotov V.V., Efremov S.M., Kirov M.Y., Fominskiy E.V., Karaskov A.M. Low-Cardiac-Output Syndrome After Cardiac Surgery. J Cardiothorac Vasc Anesth, 2017, vol. 31(1), pp. 291–308. doi: 10.1053/j.jvca.2016.05.029.

11. Thiele H., Zeymer U., Neumann F.J., et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med, 2012, vol. 367(14), pp. 1287–1296. doi: 10.1056/NEJMoa1208410.

12. Chang C.-H., Chen H.-C., Caffrey J.-L., et al. Survival Analysis After Extracorporeal Membrane Oxygenation in Critically Ill Adults: A Nationwide Cohort Study. Circulation, 2016, vol. 133(24), pp. 2423–2433. doi: 10.1161/CIRCULATIONAHA.115.019143.

13. Overgaard C.B., Dzavik V. Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation, 2008, vol. 118, pp. 1047–1056.

14. Dunser M.W., Hasibeder W.R. Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. J Intensive Care Med, 2009, vol. 24(5), pp. 293–316. doi: 10.1177/0885066609340519.

15. Rossini R., Valente S., Colivicchi F., Baldi C., Caldarola P., Chiappetta D., Cipriani M., Ferlini M., Gasparetto N., Gilardi R., Giubilato S., Imazio M., Marini M., Roncon L., di Uccio F.S., Somaschini A., Dini C.S., Trambaiolo P., Usmiani T., Gulizia M.M., Gabrielli D. ANMCO POSITION PAPER: Role of intra-aortic balloon pump in patients with acute advanced heart failure and cardiogenic shock. Eur Heart J Suppl, 2021, vol. 23(Suppl C), pp. 204–220. doi: 10.1093/eurheartj/suab074.